DDInter255 DDInter1715
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Carmustine
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Carmustine
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) causes {v} (Side Effect) Tachycardia
Tachycardia {u} (Side Effect) is caused by {v} (Compound) Carmustine
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) causes {v} (Side Effect) Tachycardia
Tachycardia {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) upregulates {v} (Gene) C5
C5 {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) upregulates {v} (Gene) C5
C5 {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is upregulated by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Carmustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Carmustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Carmustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89
Busulfan (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) upregulates C5 (Gene) and C5 (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) upregulates C5 (Gene) and C5 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Busulfan (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89